The Prescription Drug Affordability Board (PDAB) is soliciting comments informing the development of draft regulations to implement its plan to determine upper payment limits for drugs of concern. The General Assembly’s Legislative Policy Committee approved the plan last week, clearing it to move ahead to the regulatory stage. Comments should be submitted to comments.pdab@maryland.gov by November 8, 2024.
- Farxiga, Jardiance, Ozempic and Trulicity (Clinical input on Upper Payment Limits Plan for each drug)
For more information, contact NACDS’ Jill McCormack at 717-592-8977.